Enhanced safety surveillance of GSK's quadrivalent seasonal influenza vaccine in Germany and Spain (2021/2022 season) using an electronic patient-reported outcome system for vaccine safety remote monitoring.

Gaël Dos SantosTamara EckermannXavier Martínez-Gómez Jose Parra Ugo Nwoji Ignacio Salamanca de la Cueva

Published in: Influenza and other respiratory viruses (2023)

This study supports and confirms the safety profile of GSK's IIV4 in all age groups with a vaccine indication. The new electronic safety reporting method (with response rates of 75.4% following Dose 1 and 100% following Dose 2) provides an alternative for future studies to reduce the burden on sites or in case site visits are not feasible.

Keyphrases

patient reported outcomes
public health
signaling pathway
pi k akt
cell proliferation
risk factors